We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pershing Square Holdings Ltd | EU:PSH | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.65 | -1.32% | 48.65 | 47.85 | 48.80 | 49.90 | 48.00 | 49.30 | 73,353 | 16:40:00 |
From Jul 2019 to Jul 2024
Activist investor William Ackman on Monday said there will be no "crown jewel" asset sales at Valeant Pharmaceuticals International Inc. (VRX), but that the company would consider the sale on non core assets.
Mr. Ackman, who holds a board seat at the drug company, also told CNBC in an interview that Valeant's board "absolutely" would take up the issue of potential roll backs to some of the company's drug prices. The Valeant board, he said, would take up the issue "promptly."
The Pershing Square Holdings Ltd. chief executive also said that a renaming of the company is a possibility.
CNBC website: www.cnbc.com
Write to nymonitoring@dowjones.com
(END) Dow Jones Newswires
May 02, 2016 13:19 ET (17:19 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Pershing Square Chart |
1 Month Pershing Square Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
